Uhz Klinische Forschung — Clinical Trial Site

20 Registered trials

5 Currently recruiting

Organisation

Uhz Klinische Forschung

Location

Essen, Germany

Identifier

ORG-100047929

Address

Unterstrasse 75, Frintrop, 45359, Germany

Departments

#2104: Uhz Klinische Forschung
#3405
2331: Gemeinschaftspraxis Essen
3405
Gemeinschaftspraxis
Gemeinschaftspraxis Dres G. Plassmann, D. Weber, U. Weber, H. Saueressig, J. Strohmann
Hausarztzentrum
N/A
NA
Unterfrintoper Hausarztzentrum
Unterfrintroper Hausartztzentrum / UHZ Klinishe Forschung
Unterfrintroper Hausarztzentrum

Clinical trials at this site (20)

Search interface

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending

2025-523486-17-00 Obesity 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A clinical trial to learn more about the effects of DII235 in people with high levels of lipoprotein(a) Ended

2025-521912-21-00 Cardiovascular risk reduction in participants with elev 4 2026-01-26
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Overweight or Obesity 5 2025-01-29
Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended

2023-504922-20-00 Hypercholesterolemia 5 2024-08-23
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended

2023-505255-51-00 Herpes Zoster 5 2022-08-08
Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 yea… Ended

2024-512291-34-00 Respiratory Syncytial Virus Infections 5 2021-02-22
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older. Ended

2023-503763-42-00 Healthy individuals or individuals with stable comorbid 5 2023-11-03
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08